Log In
Print
BCIQ
Print
Print this Print this
 

Velphoro, sucroferric oxyhydroxide (PA21)

  Manage Alerts
Collapse Summary General Information
Company Galenica Ltd.
DescriptionOral iron-based phosphate binder
Molecular Target
Mechanism of ActionPhosphate binder
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationHyperphosphatemia
Indication Details 
Regulatory Designation

U.S. - Undisclosed Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis);
EU - Standard Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis);
Switzerland - Standard Review (Treat hyperphosphatemia in patients with chronic kidney disease (CKD) who are on dialysis)

Partner

Fresenius SE & Co. KGaA; Kissei Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today